JP2009084191A - Pharmaceutical composition for inhibiting appetite - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing a cholecystokinin excito-secretory ingredient for inhibiting appetite that has low calorie, exhibits high heat resistance/enzymolysis resistance and can be applied to a wide range of pharmaceuticals and/or foods and drinks. <P>SOLUTION: The pharmaceutical composition for inhibiting appetite comprises a component exhibiting a cholecystokinin excitosecretory action obtained by hot-water extraction of an enzyme. The hot-water extraction can be followed by further extraction with an organic solvent such as ethanol or acetonitrile. The active component can be obtained also by a protease treatment of an enzyme. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to an appetite-suppressing pharmacological composition containing a component exhibiting a cholecystokinin secretion stimulating action obtained from yeast, an appetite-suppressing food or drink containing the appetite-suppressing pharmacological composition, and the appetite-suppressing agent The present invention relates to the use of a pharmacological composition for producing a food or drink or pharmaceutical product having an appetite suppressing effect.

  The adverse effects brought about by recent improvements in food conditions and dietary changes based on high fat and high calories are not limited to developed countries, but promote a series of diseases called metabolic syndrome, and obesity is an important exacerbation factor. Recognition has been made. Nutritional guidance, surgical operations, and various appetite suppressants are being developed as methods for suppressing obesity, although some have been put to practical use, there are problems of side effects and fundamental human needs. It is difficult to suppress appetite, and it is difficult to say that there are still sufficient solutions.

  As a study for suppressing obesity, there is a method for forcibly reducing the digestibility. Examples include the development of glycolytic enzyme inhibitors and lipid substitute foods, or the elimination of lipids in ingested foods as stool without digestion. The effect is often temporary or difficult to continue to use. Ideally, it is desirable to be able to stop eating after feeling full. For that purpose, it is only necessary to be able to recognize a feeling of satiety exceeding the satisfaction after food intake by a biological signal.

  Ingestion of meals releases various peptides that can stimulate satiety in vivo. Cholecystokinin (hereinafter referred to as “CCK”) is an important regulator of human satiety, and post-meal CCK release slows gastric emptying and activates brain receptors that also suppress appetite. Produces various satiety effects. Therefore, if the CCK level in the blood can be maintained at a high level under physiological conditions, a feeling of fullness can be felt, and intake can be completed with a relatively small amount of meal, which can be expected to play an important role in combating obesity. However, since CCK itself has the major disadvantage of being inactivated by gastric enzymes, it is necessary to rely on administration into the blood to directly increase the concentration of CCK. Therefore, it is desirable not to administer CCK itself, but to develop means by which the living body itself enhances the secretion of CCK by some dietary factor (Non-Patent Documents 1 to 5).

  It has been shown that many nutrients such as proteins, lipids (especially long chain fatty acids) and calcium can promote CCK release. It has also been suggested that CCK release can be stimulated by proteins such as whey and casein, hydrolysis products of casein such as glycomacropeptides, phenylalanine, calcium and long chain fatty acids (Patent Documents 1-6). . For example, Patent Document 1 discloses oral administration of a trypsin inhibitor that increases satiety by stimulating CCK release. Trypsin inhibitors are presumed to act by suppressing negative feedback signals for cholecystokinin secretion. In this way, the trypsin inhibitor maintains the concentration of CCK, thereby sustaining fullness. Similarly, proteinase inhibitors extracted from potato have been shown to stimulate cholecystokinin release.

  However, lipid is a high-calorie substance in itself, and taking it in an effective amount is not wise for the purpose of preventing obesity, and there is a problem of heat stability even with certain proteins, so it should be added to processed foods. Considering the above, it is not a stable form.

US Pat. No. 4,491,578 Special table 2003-523368 JP-A-2004-10568 Special table 2005-538704 Special table 2006-510367 Special table 2006-514083 Ritter, R.A. C. Et al., Nepeptides 33, 387-399, 1999. Weller, A .; Science, 247, 1589-1591, 1990. Woltman, T and Reidelberger, R .; American Journal of Physiology 276, R1701-R1709, 1999 Rossetti, L.C. Diabetes, 36, 1212-1215, 1987 Ruchakoff, R.A. J. et al. Et al., Journalof Clinical Endocrinological Metabolism, 65, 395-401, 1987

  An object of the present invention is to provide an appetite suppressing composition containing a component exhibiting a yeast-derived CCK secretion stimulating action.

  As a result of intensive studies, the present inventors have found that a processed product of yeast has a CCK secretion stimulating action, and has completed the present invention.

That is, the present invention includes the following features.
(1) An appetite-suppressing pharmacological composition comprising a component that exhibits a cholecystokinin secretion stimulating action obtained from yeast.
(2) The pharmacological composition for appetite suppression according to (1), wherein the pharmacological composition containing the component comprises an extract or extract obtained by hot water extraction of yeast.
(3) The pharmacology for appetite suppression according to (2), wherein the extract or extract is an extract or extract obtained by subjecting yeast to hot water extraction and further organic solvent extraction. Composition.
(4) The pharmacological composition for appetite suppression according to (3), wherein the organic solvent is ethanol or an aqueous ethanol solution.
(5) The pharmacological composition for appetite suppression according to (3), wherein the organic solvent is acetonitrile or an acetonitrile aqueous solution.
(6) The pharmacological composition for appetite suppression according to (1), wherein the pharmacological composition containing the above-mentioned components contains a soluble fraction obtained by protease treatment of yeast or a processed product thereof.
(7) The pharmacological composition for appetite suppression according to (6), wherein the soluble fraction is an extract or extract obtained by subjecting the yeast to protease treatment and further hot water extraction.
(8) The pharmacological composition for suppressing appetite according to (6), wherein the treated product is a freeze-dried product.
(9) The pharmacological composition for appetite suppression according to any one of (1) to (8), wherein the yeast is brewer's yeast.
(10) An appetite suppressing food or drink comprising the appetite suppressing pharmacological composition according to any one of (1) to (9).
(11) The food or drink according to (10), which is a health food.
(12) An appetite-suppressing pharmaceutical product comprising the appetite-suppressing pharmacological composition according to any one of (1) to (9).
(13) Use of the pharmacological composition for appetite suppression according to any one of (1) to (9) for producing a food or drink or pharmaceutical product having an appetite suppression effect.
(14) The use according to (13), wherein the food or drink is a health food.

  As used herein, the term “appetite suppressive effect” refers to the suppression or inhibition of eating behavior by inducing or sustaining a feeling of fullness and fullness after ingestion or administration of the composition of the present invention. Refers to action.

  The term “extract” as used herein refers to a solution or liquid obtained by extracting a raw material such as yeast, its cell wall fraction, and its crushed material with a solvent. Further, the term “extract” refers to a processed product obtained by further processing the extract, and the processed product is, for example, a dried product after removing the solvent, and a purified product of the active ingredient of the present invention. Including processed products.

  The pharmacological composition for appetite suppression of the present invention is useful as a means for suppressing appetite by giving a feeling of satiety to target animals (including humans) administered / ingested based on its CCK secretion stimulating action. In addition, the pharmacological composition for appetite suppression of the present invention is not only low in calories per se, but also has very high heat resistance and resistance to enzymatic degradation. Wide application to products is possible.

  The present invention is obtained by using yeast as a raw material and extracting it with (hot) water extraction, optionally further organic solvent extraction, or treating with an enzyme, preferably protease, and optionally further (hot) water extraction. This is based on the finding that the extract, extract or processed product has a CCK secretion stimulating action.

  CCK is a gastrointestinal hormone secreted from duodenal mucosal cells, which suppresses gastric emptying of food intake, promotes pancreatic enzyme secretion, suppresses eating behavior by providing satiety, and reduces blood sugar levels. It is known to promote the secretion of the regulatory hormone insulin (Weller, A. et al., Science 247, 1589-1591, 1990; Woltman, T and Reidelberger, R. American Journal of Physiology 276 Volume, R1701-R1709, 1999; Rossetti, L. et al., Diabetes, 36, 1212-1215, 1987; and Ruchakoff, R.J., et al., Journalof Clinical Endocrinological. Metabolism, 65, 395-401, 1987). Due to such a biological function of CCK, the pharmacological composition of the present invention containing a yeast-derived CCK secretion-stimulating component can have an appetite suppressing effect.

  The yeast used as a raw material for the yeast cell wall fraction used for producing the composition of the present invention is not particularly limited as long as it belongs to the taxonomic and is an edible yeast. For example, a by-product of the beer brewing process In addition to beer yeast, wine yeast, baker's yeast, torula yeast, alcohol yeast, sake yeast, and the like can be used. More specifically, the yeast used in the present invention is not limited to this, but is not limited to this. Randy (Saccharomyces rouxii), Saccharomyces carlsbergensis or Saccharomyces pombe, etc. Squirrel (Ca Dida tropicalis), Candida lipolytica (Candida lipolytica), can be mentioned Candida-Fureberi (Candida flaveri) or Candida-Boijinyi (Candida boidinii), etc., or Rhodotorula Minyuta (Rhodotrura minuta Torla genus), and the like. In the present invention, the above yeasts can be used alone or in combination. Moreover, the use form may be either raw or dry form.

  In one embodiment of the present invention, the component exhibiting the CCK secretion stimulating action of the present invention is hot water at a temperature at which all of the enzymes used in the extraction of yeast, preferably the autolysis enzyme or yeast extract are inactivated. It can be obtained by extraction. Specifically, yeast is dispersed in appropriate water (1: 1000 to 6:10 weight ratio, preferably 5: 100 weight ratio), and homogenized using a homogenizer, stirrer, shaker, etc., and the pH is adjusted. It can be obtained by a method including heating after adjusting to neutral or the vicinity thereof and extracting with hot water.

  The temperature at the time of solvent extraction is usually in the range of 70 to 100 ° C., preferably 80 to 100 ° C., and most preferably about 90 to 100 ° C. The extraction time is 1 to 240 minutes, preferably 30 to 180 minutes, for example about 60 minutes or more.

  After extraction, the insoluble fraction can be removed by an appropriate separation means such as centrifugation or filtration to obtain a supernatant or a soluble fraction. The supernatant or soluble fraction can preferably be further subjected to drying means and grinding means. The drying method may be any method as long as it is a known method. For example, the drying method is not limited thereto, but examples thereof include an air drying method, a heat drying method, a spray drying method, and a freeze drying method. A preferred drying means is lyophilization. The pulverization method includes means such as pulverization or atomization using, for example, a pulverizer or an attritor.

  In another embodiment of the present invention, the active ingredient of the present invention is obtained by extracting the yeast with hot water as described above, preferably at a temperature at which all enzymes used in producing the autolytic enzyme and yeast extract are inactivated. Further, it can be obtained by extraction with an organic solvent. Specifically, an organic solvent is added to the water extract and kept on ice, and then the insoluble fraction is removed by an appropriate separation means such as centrifugation or filtration.

  Although the organic solvent which can be used by this invention is not limited to this, For example, ethanol, ethanol aqueous solution, acetonitrile, acetonitrile aqueous solution, isopropanol, isopropanol aqueous solution etc. can be mentioned. The amount of the organic solvent to be added is 5 to 95% by volume, preferably 20 to 70% by volume, for example, about 50% by volume, based on the extract or extract, and the extraction time is preferably 1 minute to 24 hours. Is from 1 to 360 minutes, for example about 30 minutes or more. After extraction with an organic solvent, an extract containing the active ingredient of the present invention can be obtained by drying the soluble fraction. Alternatively, the extract of the present invention can be obtained from the precipitate after the organic solvent extraction by repeating the extraction with the organic solvent exemplified above for the insoluble fraction after the organic solvent extraction. The soluble fraction and the precipitate obtained by the above method are a low molecular fraction and a high molecular fraction, respectively, and the low molecular fraction has a CCK stimulating activity higher by about 3 times or more (FIG. 2).

  In another embodiment of the present invention, the component exhibiting the CCK secretion stimulating action of the present invention can also be obtained by enzymatic treatment of yeast.

  Specifically, the component is prepared by dispersing yeast in a suitable aqueous solvent (1: 1000 to 6:10 weight ratio, preferably 5: 100 weight ratio), homogenizing, adjusting pH, and then enzyme (immobilization). And the like, and preferably by treating with protease and removing the insoluble fraction by a separation means such as centrifugation or filtration. Examples of the solvent that can be used include, but are not limited to, water and buffer solutions such as phosphate buffer, Tris buffer, citrate buffer, and acetate buffer. The homogenization can be performed using, for example, but not limited to, a polytron homogenizer, a stirrer, a shaker, an ultrasonic oscillator, and the like. The pH varies depending on the optimum pH of the enzyme used. For example, an enzyme having an optimum pH in the acidic range is used in an acidic buffer. Therefore, those skilled in the art can appropriately set and adjust an appropriate pH according to the enzyme used. Any enzyme can be used as long as it can hydrolyze yeast proteins, and examples thereof include proteases and peptidases. Proteases, particularly endoproteases, are preferred. Examples of proteases include prostheses derived from microorganisms, plants, or animals, such as, but not limited to, pepsin, orientase (22BF, 90N, 20A, etc., Aspergillus niger), chymotrypsin, trypsin, and the like. The amount of the enzyme to be added is generally 0.01 to 10% by weight, preferably 0.1 to 2% by weight, preferably 0.5 to 1% by weight, based on the substrate. The treatment time with the enzyme may vary depending on the activity of the enzyme, but is generally 5 to 240 minutes, preferably 10 to 60 minutes. About an extract, it can obtain by drying a soluble fraction like the above.

  In another embodiment of the present invention, the active ingredient of the present invention can be obtained by performing hot water extraction at a temperature at which the enzyme is deactivated after the enzyme treatment of yeast. The conditions for hot water extraction are the same as above.

  Since the composition of the present invention can be expected to have an appetite suppressing effect due to its CCK secretion stimulating action as described above, it will be useful for the prevention of diseases such as obesity, hyperlipidemia, diabetes and heart disease.

  Therefore, in another aspect of the present invention, there is provided an appetite-suppressing pharmaceutical product or food / drink (eg, health food) containing the pharmacological composition for appetite suppression of the present invention.

  The appetite-suppressing pharmaceutical product or food or drink (for example, health food) containing the appetite-suppressing pharmacological composition of the present invention may be used as a part of the pharmaceutical or food / beverage product raw material, or the pharmaceutical or food or drink It can be obtained by adding / mixing after the manufacturing process or manufacturing.

  When the composition of the present invention is used in a pharmaceutical product, the pharmaceutical product of the present invention can further contain a pharmaceutically acceptable carrier in addition to the pharmacological composition of the present invention. (Note, intramuscular injection, subcutaneous administration, intraperitoneal administration, rectal administration, transdermal administration, etc.) can be administered to subjects (including humans). Moreover, it can be set as a suitable dosage form according to an administration route. Specifically, injections such as intravenous injection and intramuscular injection, capsules, tablets, granules, powders, pills, fine granules, lozenges and other oral preparations, rectal administration agents, oily suppositories, and aqueous seats It can be prepared in various pharmaceutical forms such as an agent.

  These various preparations are commonly used excipients, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, solubilizers, preservatives. , Coloring agents, flavoring agents, stabilizers, and the like, can be produced by known methods known to those skilled in the art.

Examples of excipients include lactose, fructose, glucose, corn starch, sorbit, and crystalline cellulose. Examples of disintegrants include starch, sodium alginate, gelatin, calcium carbonate, calcium citrate, dextrin, magnesium carbonate, and synthetic silica. Magnesium acid and the like are binders such as methyl cellulose or a salt thereof, ethyl cellulose, gum arabic, gelatin, hydroxypropyl cellulose and polyvinyl pyrrolidone, etc. Lubricants are talc, magnesium stearate, polyethylene glycol, hydrogenated vegetable oil and the like However, other additives include syrup, petrolatum, glycerin, ethanol, propylene glycol, citric acid, sodium chloride, sodium nitrite and sodium phosphate, respectively. It is below.
In a preferred embodiment of the invention, the medicament of the invention is formulated as an oral formulation. At that time, it should be noted that an enteric coating or the like for avoiding decomposition in the intestinal tract is not particularly required based on the above properties of the composition of the present invention.

  When the composition of the present invention is used in a food or drink, the form of the food or drink of the present invention is not particularly limited, for example, but is not limited thereto, yogurt, drink yogurt, juice, milk, Various beverages such as soy milk, alcoholic beverages (alcoholic beverages), coffee, tea, sencha, oolong tea, sports beverages, baked confectionery such as cookies, bread, cakes and rice crackers, Japanese confectionery such as sheep candy, pudding, jelly, ice cream, etc. Confectionery such as frozen confectionery, chewing gum, candy, snacks such as crackers and chips, noodles such as udon and soba, fish paste products such as kamaboko, ham and fish sausage, miso, soy sauce, dressing, mayonnaise, sweetness Concrete such as seasonings such as ingredients, and various side dishes such as tofu, konjac, other boiled rice cakes, salads, soups, etc. It can Shimesuru.

  A preferred example of the food or drink is health food. The above-mentioned excipients and the like and the composition of the present invention can be combined to form any form such as a drink, tablet, granule, powder, gel and the like. A label to the effect of suppressing appetite can be attached to the container.

  In another embodiment of the present invention, the appetite suppressing composition or food or drink of the present invention may further contain a nutritional supplement component. Such ingredients include vitamins (eg, vitamin A, vitamin B group, vitamin E, vitamin C, vitamin D, vitamin K, niacin, pantothenic acid, folic acid, etc.), carotenoids (eg, β-carotene, lycopene, fucoxanthin, etc.), Minerals (eg seaweed components, CCM, heme iron, iron salt system, whey calcium, fermented calcium lactate, beef bone calcium, salmon calcium, eggshell calcium, etc.), various plants and their extracts, purified products and fractions (E.g. psyllium, chlorella, spirulina, garlic, ginkgo biloba, gymnema, tochu leaf, shiso leaves, pearl barley, soy globulin, rutin, green tea extract, theanine, polyphenols, licorice, yucca, soy saponin, caffeine, huahua Torberry extract, Champignon extract, Garcinia cambodia Etc.), microorganisms and their growth factors and microbial products (for example, lactic acid bacteria, yeast, lactic acid bacteria growth factors, etc.), dietary fiber and its enzymatic degradation products (for example, apple fiber, corn fiber, starch-derived dietary fiber, indigestible dextrin, Guar gum enzyme degradation product, sweet potato fiber, soybean fiber, seaweed fiber, mushroom fiber, tea fiber, acidic polysaccharide, plant mucilage, wheat bran, etc.), animal body and its extract, purified product, degraded product and product (for example, Royal jelly, propolis, oyster extract, chitin, chitosan, taurine, collagen, gelatin, etc.), various oligosaccharides (eg, galactooligosaccharide, xylooligosaccharide, soybean oligosaccharide, fructooligosaccharide, isomaltoligosaccharide, whey oligosaccharide, etc.), lipid ( For example, unsaturated fatty acids (DHA, EPA, etc.), phospholipids, salatrim, etc.), each Seed proteins and proteolysates (eg corn protein, soy protein, TMP (total milk protein), lactalbumin, casein, whey, glutathione, soy peptide, egg white peptide, glutamine peptide, etc.), wheat germ such as defatted germ It is done.

  The dose or intake of the composition of the present invention as an active ingredient in the pharmaceutical of the present invention can be appropriately determined according to the age, sex, body weight, symptom, administration time, dosage form, administration method, etc. of the subject. . In the case of oral administration, the dose or intake is usually 50 to 1000 mg / kg body weight, preferably 100 to 200 mg / kg body weight per day per adult. The dose or intake may be administered once a day or divided into several times.

  Moreover, when ingesting as food / beverage products (preferably health food), content as an active ingredient in food / beverage products (preferably health food) is 0.05-5 weight% normally, Preferably it is 0.1-0.1%. It is about 0.3% by weight, and it may be ingested so that the intake amount is 0.2 to 20 g, preferably 0.4 to 1.2 g per day for an adult as an active ingredient.

Example 1: Extraction of yeast hot water extract 10 g of debittered yeast was dispersed in 200 mL of water, homogenized with a polytron homogenizer, and then adjusted to pH 7 by adding hydrochloric acid or sodium hydroxide. Thereafter, it was treated with boiling water (100 ° C.) for 60 minutes, then cooled and allowed to stand to room temperature. The pH was adjusted to 7 again using hydrochloric acid or sodium hydroxide, and the supernatant was separated by centrifugation (15 minutes at 3000 to 5000 rpm). Next, the supernatant was filtered through a filter, freeze-dried, and processed with a pulverizer after completion to obtain a powder.

Example 2 Extraction of Yeast Pepsin Treated Product 10 g of debittered yeast was dispersed in 200 mL of phosphoric acid solution (0.02N H ₃ PO ₄ solution), homogenized with a polytron homogenizer, and then 20N H ₃ PO ₄ was added. The pH was adjusted to 1.85. Thereafter, pepsin (Sigma) was added at 0.5 to 1% by weight based on the substrate, and kept at 37 ° C. (10 minutes or 60 minutes) with stirring.
After completion of the reaction, the enzyme was inactivated by immersing in boiling water for 20 minutes. Next, the mixture was cooled to room temperature, Ca (OH) ₂ was added and the pH was adjusted to 7 again, and then separated into a supernatant and a precipitate by centrifugation (3,000 to 5000 rpm for 15 minutes).
The supernatant was frozen once at -80 ° C., thawed at room temperature, filtered through a filter, and subjected to lyophilization.

Example 3: Extraction of yeast enzyme-treated product 10 g of debittered yeast was dispersed in 200 mL of water, homogenized with a polytron homogenizer, and then adjusted to pH 7 by adding hydrochloric acid or sodium hydroxide. Thereafter, the mixture was heated to 55 ° C., and orientase 22BF, 90N or 20A (manufactured by HBI Co., Ltd.) was added at 0.5% by weight with respect to the substrate, respectively, and kept at 55 ° C. (60 minutes) with stirring. did.
After completion of the reaction, the enzyme was inactivated by immersing in boiling water for 20 minutes. Next, the mixture was cooled to room temperature, hydrochloric acid or sodium hydroxide was added to adjust the pH to 7 again, and then the supernatant and the precipitate were separated by centrifugation (3,000 to 5000 rpm for 15 minutes).
Thereafter, the supernatant was filtered through a filter and subjected to lyophilization.

Example 4: Regarding the fractionated yeast hot water extract after extraction of hot water with a low molecular weight fraction and a high molecular fraction , the sample was appropriately diluted (diluted approximately 20 times) so that it would be 50% by volume in the solution. Acetonitrile was added and kept on ice for over 30 minutes. Thereafter, the supernatant and the precipitate were separated by centrifugation (3000 rpm, 4 ° C. for 15 minutes).
The supernatant was lyophilized as it was. For the precipitate, 50% by weight of acetonitrile was further added, the precipitate was washed, kept on ice for 30 minutes or more, and then separated into a supernatant and a precipitate by centrifugation (3000 rpm, 15 minutes at 4 ° C.). The precipitate was lyophilized.

Example 5: Evaluation of CCK secretion stimulating activity of yeast hot water extract and yeast enzyme-treated product The preparations prepared in Examples 1 to 4 were evaluated by STC-1 cells secreting CCK (Sufian MK et al., Biosci Biotechnol). Biochem. 2006, 70: 1869-1874, Choi S et al., Am J Physiol Gastrointest Liver Physiol. 2007, 8). CCK secretion was performed according to the method described in Sufian MK et al., Biosci Biotechnol Biochem. 2006, 70: 1869-1874., Choi S et al. (Supra). The following culture conditions were used: a modified eagle medium supplemented with 10% fetal bovine serum, penicillin 100 U / ml, streptomycin 100 μg / ml, and a wet state of 5% CO ₂ at 37 ° C.
For secretion evaluation, cells cultured under the above conditions were separately transplanted into a container, cultured for 2 to 3 days, and after reaching a steady state, washed with HEPES buffer, added with each sample, and cultured for 60 minutes. The supernatant was collected and CCK was quantified using a commercially available ELISA kit (Phoenix Pharmaceuticals Inc, Belmont CA, USA).

result
As shown in FIG. 1 for CCK secretion stimulation , each sample was prepared to 5 mg / ml for evaluation. A strong CCK secretion stimulating activity was found in the pepsin degradation product and hot water extract of dry brewer's yeast. Since the activity is also retained in the pepsin degradation product, it is presumed that it is a fraction having very high heat resistance, high enzymatic degradation resistance, or both characteristics. From these things, it is estimated that it has a physical property different from the component derived from the conventional milk protein.

  As shown in FIG. 2, each sample was prepared at 5 mg / ml for evaluation. The hot water extract described in Example 1 has a higher activity than the β-conglycinin pepsin degradation product (BconP) used as a positive control, and the activity is a low molecular fraction described in Example 4 (50% acetonitrile soluble). There was a lot of activity. Activity was also present in the high molecular fraction of Example 4, but it was shown to be lower than the low molecular fraction.

  As shown in FIG. 3, each sample was prepared at 5 mg / ml and subjected to evaluation. A brewer's yeast degradation product was prepared using three types of proteases (Orientase 22BF (basic), 90N (neutral), 20A (acidic)) having different optimum pH values described in Example 3, and CCK releasing activity was measured. As a result of measurement, all degradation products showed activity equal to or higher than that of the positive control β-conglycine, and equal to or higher than that of the hot water extract or pepsin degradation product. From these, the active fraction is very difficult to be affected by proteolytic enzymes, or the activity is also observed in peptides or hot water extracts produced by the degradation process. It is presumed that there is a high possibility of including compounds.

FIG. 1 shows the amount of CCK secretion from STC-1 cells treated with a hot water extract of yeast or a treated product of yeast pepsin. FIG. 2 shows the amount of CCK secretion from STC-1 cells treated with a hot water extract of yeast and a low molecular fraction and a high molecular fraction produced by organic solvent (acetonitrile) extraction after hot water extraction. FIG. 3 shows CCK secretion from STC-1 cells treated with yeast hot water extract, treated with yeast pepsin, and treated with yeast by orientase 22BF, 90N and 20A (basic, neutral and acidic proteases, respectively). Indicates the amount.

Claims (14)

  An appetite-suppressing pharmacological composition comprising a component having a cholecystokinin secretion stimulating action obtained from yeast.   The pharmacological composition for appetite suppression according to claim 1, wherein the pharmacological composition containing the component comprises an extract or extract obtained by hot water extraction of yeast.   The pharmacological composition for appetite suppression according to claim 2, wherein the extract or extract is an extract or extract obtained by subjecting yeast to hot water extraction and further organic solvent extraction.   The pharmacological composition for appetite suppression according to claim 3, wherein the organic solvent is ethanol or an aqueous ethanol solution.   The pharmacological composition for appetite suppression according to claim 3, wherein the organic solvent is acetonitrile or an acetonitrile aqueous solution.   The pharmacological composition for appetite suppression according to claim 1, wherein the pharmacological composition containing the component comprises a soluble fraction obtained by a protease treatment of yeast or a processed product thereof.   The pharmacological composition for appetite suppression according to claim 6, wherein the soluble fraction is an extract or extract obtained by subjecting yeast to protease treatment and further hot water extraction.   The pharmacological composition for appetite suppression according to claim 6, wherein the treated product is a freeze-dried product.   The pharmacological composition for appetite suppression according to any one of claims 1 to 8, wherein the yeast is beer yeast.   An appetite-suppressing food or drink comprising the pharmacological composition for appetite suppression according to any one of claims 1 to 9.   The food or drink according to claim 10, wherein the food or drink is a health food.   An appetite-suppressing pharmaceutical product comprising the pharmacological composition for appetite suppression according to any one of claims 1 to 9.   Use of the pharmaceutical composition for appetite suppression of any one of Claims 1-9 for manufacturing the food-drinks or pharmaceutical which have an appetite suppression effect.   14. Use according to claim 13, characterized in that the food or drink is a health food.

Images